MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

MXCT 10.11.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-06
Name of Upcoming Event:Earnings Conference Call
Full Press ReleaseSEC FilingsOur MXCT Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Holding(s) in Company

Recent Filings

    ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

    Earnings Conference Call DetailsInvestors interested in listening to the conference call are required toregister online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website athttps://investors.maxcyte.com/.

    About MaxCyte

    At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERTTM platform, which is based on our Flow Electroporation®technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more atmaxcyte.comand follow us onXandLinkedIn.

    MaxCyte Contacts:

    US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com

    US Media RelationsSpectrum ScienceJordan Vinesjvines@spectrumscience.com+1 540-629-3137

    Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500

    UK IR AdviserICR ConsiliumMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@consilium-comms.com

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com